<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nosocomial infections in the intensive care unit: Epidemiology and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nosocomial infections in the intensive care unit: Epidemiology and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nosocomial infections in the intensive care unit: Epidemiology and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dror Marchaim, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith Kaye, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony Harris, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although intensive care units (ICUs) account for fewer than 10 percent of total beds in most hospitals, more than 20 percent of all nosocomial infections are acquired in ICUs [<a href="#rid1">1</a>]. ICU-acquired infections account for substantial morbidity, mortality, and expense.</p><p>The general epidemiology of nosocomial infections and antimicrobial resistance in ICUs will be discussed here. The epidemiology, management, and prevention of specific nosocomial infections in the ICU, namely catheter-related bloodstream infections (CRBSIs), ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infections (CAUTIs), will be discussed briefly here and in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a> and  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults"</a> and  <a class="medical medical_review" href="/d/html/8095.html" rel="external">"Complications of urinary bladder catheters and preventive strategies"</a>.)</p><p></p><p>Issues related to surgical site infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a> and  <a class="medical medical_review" href="/d/html/4044.html" rel="external">"Overview of control measures for prevention of surgical site infection in adults"</a>.)</p><p>Infection prevention and ICU care of patients with COVID-19 are also presented elsewhere. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a> and  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p class="headingAnchor" id="H2085564435"><span class="h1">EPIDEMIOLOGY OF NOSOCOMIAL INFECTIONS</span></p><p class="headingAnchor" id="H4083849919"><span class="h2">Common noscomial infections</span><span class="headingEndMark"> — </span>The most common and clinically important infections acquired in the ICU are those associated with the supportive devices that patients in the ICU often require. These include intravascular catheter-related bloodstream infection (CRBSI), ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infection (CAUTI).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravascular catheter-related infections</strong> – Arterial and central venous catheters are frequently used in critical care patients because of the need for hemodynamic monitoring and intravenous therapeutics. Bloodstream infections involving these catheters are common in ICUs and are associated with significant morbidity and mortality [<a href="#rid2">2</a>]. In addition, in the United States, the cost burden of these infections on health care facilities was exacerbated after the Centers for Medicare and Medicaid Services stopped reimbursing hospitals for catheter-related bloodstream infections (CRBSIs) in October 2008. These infections are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventilator-associated pneumonia</strong> – Ventilator-associated pneumonia (VAP) is infection of lung tissue that develops 48 hours or more after intubation in mechanically ventilated patients. Nosocomial pneumonia occurs frequently in the setting of endotracheal intubation and mechanical ventilation [<a href="#rid3">3</a>]. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter-associated urinary tract infection</strong> – Urinary tract infections (UTIs) are among the most common nosocomial infections [<a href="#rid4">4</a>]. While most catheter-associated UTIs do not cause severe morbidity and mortality or significantly increase hospital costs, the cumulative impact of these frequent infections is large [<a href="#rid5">5</a>]. In the United States, CAUTIs are responsible for 900,000 additional hospital days per year and contribute to &gt;7000 deaths [<a href="#rid6">6,7</a>]. CAUTIs are the second most common cause of nosocomial bloodstream infection (ie, urosepsis), which have an attributable mortality of approximately 15 to 25 percent [<a href="#rid8">8-12</a>]. The Centers for Medicare and Medicaid Services does not reimburse hospitals for CAUTIs, which further increases the cost burden of these infections on hospitals in the United States.</p><p></p><p>In addition to actual infection, asymptomatic bacteriuria often leads to significant laboratory testing and inappropriate antimicrobial utilization in the absence of an established infection [<a href="#rid11">11,13</a>]. Inappropriate treatment of asymptomatic bacteriuria has been associated with adverse clinical outcomes [<a href="#rid14">14</a>]. The urinary tract in catheterized patients also serves as a reservoir for multidrug-resistant bacteria, which can cause either infection or asymptomatic bacteriuria [<a href="#rid11">11</a>]. Issues related to CAUTIs are discussed separately. During the work-up of a patient for suspected infection, if a non-urinary source of infection is suspected, routine urine culture should be avoided. (See  <a class="medical medical_review" href="/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults"</a> and  <a class="medical medical_review" href="/d/html/8090.html" rel="external">"Placement and management of urinary bladder catheters in adults"</a>.)</p><p class="headingAnchor" id="H353071225"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Most studies of ICU-associated nosocomial infections come from industrialized countries. According to the United States Centers for Disease Control and Prevention (CDC), ICU patients accounted for 55,870 of 78,342 total device-related infections (71 percent) in US acute care hospitals in 2020 [<a href="#rid15">15</a>]. Specifically, 50 percent of CRBSIs, 49 percent of CAUTIs, and 96 percent of ventilator-associated events (VAEs) occurred in patients in the ICU.</p><p>Device-specific rates of nosocomial infections in United States ICUs were as follows [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CRBSI: 0.86 cases per 1000 catheter-days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventilator-associated events (VAEs, including VAP): 9 cases per 1000 ventilator-days [<a href="#rid16">16</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CAUTI: 1 case per 1000 catheter-days</p><p></p><p>The rates of ICU-associated infection may even be higher in resource-limited countries, as illustrated by a multicenter prospective cohort surveillance study of 46 hospitals in Central and South America, India, Morocco, and Turkey [<a href="#rid17">17</a>]. An overall rate of 14.7 percent (or 22.5 infections per 1000 ICU days) was observed. The following rates were found for specific devices:</p><p class="bulletIndent1"><span class="glyph">●</span>CRBSI: 12.5 cases per 1000 catheter-days (range 7.8 to 18.5 cases)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VAP: 24.1 cases per 1000 ventilator days (range 10.0 to 52.7 cases)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CAUTI: 8.9 cases per 1000 catheter days (1.7 to 12.8 cases)</p><p></p><p>A subsequent study by the same international group reported results from 98 ICUs from Latin America, Asia, Africa, and Europe [<a href="#rid18">18</a>]. Despite the fact that device utilization was remarkably similar to that reported from ICUs in the United States, rates of device-associated nosocomial infection were markedly higher in the ICUs from resource-limited countries.</p><p class="headingAnchor" id="H3689694987"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Several factors contribute to the high incidence of these infections in the ICU:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with patients in the general hospital population, patients in ICUs have more chronic comorbid illnesses and more severe acute physiologic derangements. These clinical factors are felt to lead to relative immunosuppression among ICU patients [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The high frequency of indwelling catheters among ICU patients provides a portal of entry of organisms into vital body organs and sites. The use and maintenance of these catheters necessitate frequent contact with health care personnel, which predispose patients to colonization and infection with nosocomial pathogens. In addition, equipment associated with the proper maintenance of these devices might serve as reservoirs and vectors for pathogens and be related to horizontal patient-to-patient transmission of pathogens [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multidrug-resistant pathogens, such as methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), vancomycin-resistant enterococci (VRE), <em>Acinetobacter baumannii</em>, Enterobacteriaceae that produce extended-spectrum beta-lactamases and/or carbapenemases (eg, ESBLs and CREs, respectively), and carbapenem-resistant <em>Pseudomonas aeruginosa</em>, are all being isolated with increasing frequency in ICUs [<a href="#rid21">21,22</a>]. Infections caused by these resistant pathogens are difficult to treat and are associated with increased morbidity, mortality, and costs [<a href="#rid23">23,24</a>]. (See <a class="local">'Prevalence'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with patients in the general hospital population, patients in ICUs are subjected to increased selective pressure due to extensive antibiotic use in ICUs, which often favors one microorganism's survival over others. Increased colonization pressure is also present in ICUs and occurs when one microorganism becomes increasingly prevalent in the ICU environment and on healthcare workers and patients, thereby making containment of spread more difficult. [<a href="#rid19">19,25</a>].</p><p></p><p class="headingAnchor" id="H1749999274"><span class="h1">EPIDEMIOLOGY OF ANTIBIOTIC-RESISTANT ORGANISMS</span></p><p class="headingAnchor" id="H25151042"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The rate of resistance among bacterial pathogens recovered in intensive care units (ICUs) has steadily risen over the years. Among isolates reported to the United States Centers for Disease Control and Prevention (CDC) from hospital wards and ICUs between 2015 and 2017, resistance was common in pathogens that caused device-related infections [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>34 percent of <em>Enterococcus </em>were vancomycin-resistant (ie, VRE).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>48 percent of <em>S. aureus </em>isolates were methicillin-resistant (ie, MRSA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>43 percent of <em>A. baumannii</em> isolates were resistant to carbapenems. An additional 43 percent were multidrug-resistant (ie, resistant to at least three of the following classes: extended-spectrum cephalosporins, fluoroquinolones, aminoglycosides, carbapenems, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, and <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>21 percent of <em>P. aeruginosa</em> isolates were resistant to carbapenems. Significant resistance was also reported to fluoroquinolones (26 percent), cephalosporins (eg, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>; 20 percent), <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (15 percent), aminoglycosides (14 percent), and combinations of agents from at least three different classes (14 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>21 percent of <em>E. coli </em>isolates were resistant to cephalosporins (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>) and an additional 10 percent were resistant to at least three different classes. Resistance to fluoroquinolones was 38 percent and was 0.7 percent to carbapenems.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>21 percent of selected <em>Klebsiella</em> spp were resistant to cephalosporins (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>) and an additional 13 percent were resistant to at least three different classes. Resistance to carbapenems was 7 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>11 percent of <em>Enterobacter </em>spp were resistant to <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> and an additional 7 percent were resistant to at least three of the following agents: cefepime, fluoroquinolones, aminoglycosides, carbapenems, and <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>. Resistance to carbapenems was 6 percent.</p><p></p><p>The emergence of broad-spectrum resistance among gram-negatives (<em>A. baumannii</em>, <em>P. aeruginosa</em>, and some Enterobacterales) is particularly worrisome since therapeutic options are scarce, and sometimes no effective antimicrobial agent is available at all [<a href="#rid27">27</a>]. Additional emerging threats are the non-glucose fermenting gram-negative bacilli that are intrinsically resistant to carbapenems (eg, <em>Stenotrophomonas maltophilia</em>, <em>Burkholderia cepacia</em>, <em>Achromobacter xylosoxidans</em>) [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases", section on 'Treatment options'</a> and  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Approach to treatment'</a> and  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Management of multidrug-resistant organisms'</a>.)</p><p>Two additional common and significant pathogens in ICU infections are <em>Clostridioide difficile</em> and <em>Candida auris</em>. These are not "traditional" multidrug-resistant organisms but risk factors for infections due to these pathogens are similar to those associated with multidrug-resistant organism infections, and thus the affected populations are similar [<a href="#rid29">29,30</a>]. These pathogens are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Certain characteristics increase the risk of infections with multidrug-resistant pathogens in ICUs by contributing to increased selective pressure and/or increased colonization pressure [<a href="#rid25">25,31,32</a>]. Specifically, risk factors for resistant infections reported from ICUs include the following [<a href="#rid33">33-39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of functional independence and/or decreased cognition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of underlying comorbid conditions (eg, diabetes, renal failure, malignancies, immunosuppression) and higher severity of acute illness indices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long duration of hospitalization prior to the ICU admission, including interinstitutional transferring (particularly from nursing homes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequent encounters with health care environments (eg, hemodialysis units, ambulatory daycare clinics).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequent contact with health care personnel concurrently caring for multiple patients, whose hands can serve as vehicles for transfer of pathogens between patients. Shared equipment and contaminated environments can also serve as reservoirs and/or vectors that contribute to acquisition of infections in the ICU.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of indwelling devices such as central venous catheters, urinary catheters, and endotracheal tubes, which bypass natural host defense mechanisms and serve as portals of entry for pathogens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent surgery or other invasive procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of antimicrobial therapy prior to the ICU admission, which creates selective pressure promoting the emergence of multidrug-resistant bacteria.</p><p></p><p>The association between prior receipt of antibiotics and infection with drug-resistant organisms has been demonstrated in several studies and by various methodologies. In case-control studies, exposure to antibiotics has consistently been associated with the emergence of resistance to that same or a different class of antimicrobial agent [<a href="#rid40">40</a>]. As an example, receipt of fluoroquinolones has been linked to the emergence of piperacillin-resistant <em>P. aeruginosa</em> [<a href="#rid41">41</a>]. One study demonstrated that even a relatively short exposure to <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> in ICU patients was associated with a significant increase in carriage of imipenem-resistant gram-negative bacilli [<a href="#rid42">42</a>]. In a separate study, antibiotic exposure was the strongest single predictor for infection with extensively drug-resistant gram-negative pathogens [<a href="#rid40">40</a>]. The association between certain antibiotic use and emergence of resistance has also been supported by studies that used longitudinal time-series analyses to determine rates of resistance when various antibiotic agents were more commonly used at a particular institution [<a href="#rid43">43</a>] and studies that demonstrate reductions in multidrug-resistant pathogens with the implementation of antimicrobial stewardship programs and various strategies to minimize unnecessary antimicrobial use [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Infections caused by multidrug-resistant pathogens are associated with increased mortality, length of hospital stay, and hospital costs [<a href="#rid45">45-51</a>]. Patients with infections due to multidrug-resistant organisms usually are chronically or acutely ill and at risk of dying from underlying serious and complex medical illnesses. However, a number of factors related to the difficulties of choosing antibiotics for multidrug-resistant bacteria independently predispose to poor outcomes. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Multidrug-resistant pathogens are more frequently resistant to empiric antimicrobial regimens than are susceptible organisms. Thus, there are often delays in initiation of appropriate, effective antimicrobial therapy in the treatment of multidrug-resistant organisms [<a href="#rid52">52</a>]. These delays are independent predictors of mortality in severe sepsis and thus contribute to the increased mortality rates associated with resistant infections [<a href="#rid47">47,53-58</a>]. As an example, in a study of patients with septic shock, each hour of delayed appropriate therapy in the first six hours of infection was associated with an average decrease in survival of 7.6 percent [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Choosing a regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial resistance often precludes the use of optimal "first-line" antimicrobial agents and necessitates the use of "second-line" agents with inferior bactericidal activity and unfavorable pharmacokinetic and/or pharmacodynamic properties [<a href="#rid55">55</a>]. When "second line" agents are required to treat a resistant organism, adverse patient outcomes sometimes result [<a href="#rid49">49,50,60-64</a>]. As an example, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> is commonly used to treat MRSA since anti-staphylococcal penicillins (eg, <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>) and first-generation cephalosporins (eg, <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>) are not active against the organism. However, vancomycin does not possess strong bactericidal activity and is associated with an increased risk for renal insufficiency compared with beta-lactams. In several clinical studies, vancomycin was inferior to beta-lactam agents in treating methicillin-susceptible <em>S. aureus</em> infections [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p></p><p>Another factor that may contribute to poor outcomes among patients with infections due to certain multidrug-resistant pathogens is the virulence properties of the organism. In clinical studies, it is often unclear whether worse outcomes in patients with multidrug-resistant infections are due to increased virulence of the organism or to the higher rate of serious comorbidities and suboptimal antibiotic therapy in patients with multidrug-resistant pathogens [<a href="#rid66">66,67</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Strategies to prevent the emergence and spread of multidrug-resistant bacteria in intensive care units (ICUs) can be divided into two major categories: strategies that attempt to improve the efficacy and utilization of antimicrobial therapy (reducing selective pressure) and infection control measures (reducing colonization pressure) [<a href="#rid55">55,68-70</a>]. It is most efficacious to combine the two approaches [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Antibiotic utilization controls</span><span class="headingEndMark"> — </span>Incorporating antibiotic stewardship programs (often involving clinicians, infectious diseases experts, and pharmacists) into specific hospital settings such as the ICU can comprehensively address the goal of reducing infections of resistant bacterial strains. The programs promote the effective and safe use of antimicrobial agents, evaluate and guide formulary decisions, and implement educational programs to improve antimicrobial utilization [<a href="#rid70">70-74</a>]. The specifics of antibiotic stewardship programs are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/13943.html" rel="external">"Antimicrobial stewardship in hospital settings"</a>.)</p><p>Antimicrobial stewardship programs in the ICU setting have been impactful and associated with decreases in drug-resistant bacteria in some settings. As an example, in a study of two ICUs in the United States that implemented a comprehensive antimicrobial stewardship program, the proportion of hospital-acquired infections caused by certain multidrug-resistant gram-negative bacilli, including <em>P. aeruginosa</em>, <em>A. baumannii</em>, and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, decreased from 37.4 percent in 2001 to 8.5 percent in 2008 [<a href="#rid44">44</a>]. The rate of hospital-acquired infections per 1000 patient-days that were caused by these multidrug-resistant organisms declined by 0.78 per year. Similarly, in a study of an ICU in Melbourne, Australia, which implemented an antimicrobial stewardship program, 2838 gram-negative bacilli were isolated from clinical cultures over seven years, and, over this time, there were significant increases in susceptibility of <em>P. aeruginosa</em> to <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> (18.3 percent per year, p = 0.009) and <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (11.6 percent per year, p = 0.02) compared with trends recorded prior to the stewardship program [<a href="#rid75">75</a>]. Improvements in the rates of gentamicin and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> susceptibility were also noted among <em>Enterobacter</em> spp.</p><p>There may be concerns that antibiotic stewardship may result in a delay in the initiation of appropriate antimicrobial therapy, which has been associated with poor clinical outcomes with infections caused by multi- and extensively drug-resistant infections [<a href="#rid52">52,53</a>]. However, a meta-analysis of five studies found that implementation of antimicrobial stewardship programs in ICUs was not associated with increased mortality (pooled relative risk 1.03, 95% CI 0.93-1.14), thus providing some reassurance that there is no clear evidence of unintended deleterious effects of stewardship programs on mortality in the ICU setting [<a href="#rid76">76</a>].</p><p>There is no role for rotating antibiotic prescription practices by changing empiric regimens in an attempt to curb emergence of resistance [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Infection control measures</span><span class="headingEndMark"> — </span>Strategies to prevent the emergence of multidrug-resistant organisms that do not involve changes in antimicrobial utilization (which impacts selective pressure) primarily involve infection control measures (which impact colonization pressure and patient-to-patient transmission). Careful attention to these activities has been used to contain outbreaks of resistant organisms [<a href="#rid79">79-82</a>]. Adherence to hand hygiene, daily bathing with <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>, and implementation of device-specific strategies to decrease infection should be performed on a routine basis for all patients in an ICU [<a href="#rid69">69</a>]. For targeted reduction of methicillin-resistant <em>S. aureus </em>(MRSA), intranasal <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> can be used [<a href="#rid83">83</a>]. Use of chlorhexidine dressings are effective in reducing central line-associated bloodstream infection (CLABSI), including CLABSI due to resistant pathogens [<a href="#rid84">84</a>]. Contact precautions are warranted for patients infected or colonized with resistant organisms, patients with wound drainage that cannot be contained by dressings, and for patients with diarrhea. Surveillance for drug-resistant organisms is also important for identification and control of epidemic and endemic rates of resistance. Enhancing the regulation, the monitoring, and the processes for environmental cleaning is an additional established measure to contain the spread of multidrug-resistant organisms in the ICU [<a href="#rid85">85</a>]. New technologies (eg, ultraviolet light, hydrogen peroxide vapor) to reduce contamination of room air and surfaces are emerging; some such interventions can be performed while the room is occupied, but none negate the need for thorough cleaning, and data are scarce regarding their ultimate impact on preventing ICU infections or multidrug-resistant organism acquisitions [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H353071058"><span class="h3">Hand hygiene</span><span class="headingEndMark"> — </span>There is <strong>no</strong> substitute for good hand hygiene compliance. Alcohol-based hand hygiene is more effective than traditional soap and water in cleansing hands of bacteria; in addition, no sink or towels are necessary, and alcohol foam is no more abrasive to hands than antiseptic soap and water [<a href="#rid86">86,87</a>]. Alcohol gel/foam is not appropriate for hands that are visibly soiled or for health care personnel caring for patients with <em>C. difficile</em> infection (or other spores-forming organisms) since the foam does not inactivate <em>C. difficile</em> toxins and does not kill the spores themselves. Antiseptic soap and water are also recommended while caring for patients with diarrhea or for patients with noncontained wounds. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>.)</p><p class="headingAnchor" id="H353071023"><span class="h3">Contact precautions, cohorting, and dedicated staff</span><span class="headingEndMark"> — </span>Wearing gown and gloves when entering a patient room and removing them prior to or shortly after exiting (but still adjacent to patient's close environment) may decrease transmission of multidrug-resistant bacteria, including MRSA, vancomycin-resistant enterococci (VRE), and carbapenem-resistant and ESBL-producing gram-negative organisms (<em>A. baumannii</em>, <em>P. aeruginosa</em>, Enterobacterales). These precautions should be routinely implemented when caring for ICU patients who have a history of or are found to have infection or colonization with resistant organisms. Evidence supporting this practice is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control", section on 'Contact precautions'</a> and  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases", section on 'Infection control and antibiotic stewardship'</a> and  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p>The issue of whether to use universal contact precautions for every patient in the ICU, regardless of colonization history, is a matter of ongoing debate. Although this may be a reasonable practice in outbreak settings or in institutions that have a high rate of colonization or infection with drug-resistant bacteria, routine use of universal contact precautions is not yet supported by strong scientific evidence.</p><p>During the COVID-19 pandemic, despite widespread usage of universal contact precautions in some ICUs, device-related hospital-acquired infections rates increased [<a href="#rid88">88</a>]. The increase may have been due to altered device maintenance practices and lack of adherence to infection control practices and procedures, executed as well by replacing nonsufficiently trained personnel during the pandemic.</p><p>Some observational studies prior to the COVID-19 pandemic have suggested a decrease in transmission rates of drug-resistant organisms with universal contact precautions [<a href="#rid89">89-91</a>]. However, a large cluster-randomized trial failed to demonstrate a statistically significant benefit of universal use of contact precaution measures [<a href="#rid92">92</a>]. In this trial, 20 medical and surgical ICUs were randomly assigned to practice universal gown and glove use for all patients (intervention) or standard care with gown and glove use for only those patients known to be infected or colonized with antibiotic-resistant bacteria (control). Overall, 26,180 patients were followed over the three-month baseline period prior to implementation of the intervention and the 10-month study period following it. Compliance with gown and glove use was high, ranging from 80 to 86 percent. The intervention did not reduce the primary combined endpoint of MRSA or VRE acquisitions compared with baseline rates to a greater extent than the control (reduction from 21.4 to 16.9 versus 19.0 to 16.3 acquisitions per 1000 patient days in the intervention and control groups, respectively). The intervention did reduce MRSA acquisitions by 2.98 acquisitions per 1000 patient days (95% CI 0.38-5.58) more than the control; however, the baseline rate of MRSA acquisition was higher in the intervention group, so acquisition rates at the end of the study period were comparable between the two groups. Universal use of contact precaution measures has not been demonstrated to significantly reduce the acquisition of other drug-resistant organisms including gram-negative bacilli and <em>C. difficile </em>[<a href="#rid93">93,94</a>].</p><p>In the trial, universal gown and glove use led to one fewer health care personnel visit per patient on average, but there was no excess of adverse patient events with this practice. This is in contrast with earlier observational studies that had reported adverse effects associated with implementation of universal contact precautions (eg, increased rates of falls, pressure ulcers, dissatisfaction of patients with their treatment, and less documented care safety) [<a href="#rid95">95,96</a>]. Long-term consequences of contact isolation precautions are yet unknown.</p><p>In another multicenter trial, contact isolation practices were observed among health care workers; as the proportion of patients in contact isolation increased, compliance with contact isolation precautions decreased [<a href="#rid97">97</a>]. A threshold for staff compliance (approximately 40 percent of patients on contact precautions) was noted.</p><p>Gowns and gloves should always be worn while caring for patients with wound drainage that cannot be<strong> </strong>contained<strong> </strong>by dressings. In addition, gown and gloves should always be removed prior to or immediately after leaving a patient's room/unit.</p><p>An additional potential control measure is geographically cohorting carriers of the same multidrug-resistant organism and assigning dedicated nursing staff to such patients. In one outbreak of carbapenem-resistant Enterobacteriaceae, the outbreak was contained only after implementation of dedicated cohorting [<a href="#rid98">98</a>]. However, a single unit for care of patients with multiple different types of multidrug-resistant organisms should be avoided, since genes conferring resistance can cross between species [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H353071051"><span class="h3">Patient bathing/decolonization</span></p><p class="headingAnchor" id="H2346500908"><span class="h4">Patient bathing</span><span class="headingEndMark"> — </span>We suggest daily <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing for all ICU patients. Bathing patients daily with chlorhexidine gluconate (CHG), an antiseptic agent with broad-spectrum activity against many organisms, is an effective method of decreasing both hospital-acquired infections (ie, bloodstream infections, urinary tract infections [UTIs], surgical-site infections, and ventilator-associated pneumonia [VAP]) and colonization with drug-resistant organisms among patients in the ICU, as demonstrated in many studies [<a href="#rid83">83,100-114</a>]. Despite limitations of some of these studies, our recommendation is based on the apparent benefits, the low rate of associated adverse effects, and the relative ease of implementation. </p><p>Chlorhexidine-impregnated cloths or <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> soaked washcloths should be firmly massaged over all patient body surfaces and skin folds below the jaw line except for the face. Most larger trials that evaluated chlorhexidine bathing used this approach with impregnated cloths [<a href="#rid83">83,104</a>]. It is uncertain whether bathing with a washcloth soaked with liquid chlorhexidine would result in similar effects, but this may be more accessible and less expensive than premade cloths. If a soaked washcloth is used, large amounts of water should be avoided (in order to retain an effective CHG concentration [ie, approximately 4 percent]), and care should be taken to avoid getting catheter dressing wet, which may be associated with an increased rate of catheter exit-site infections [<a href="#rid115">115</a>]. Reusable basins have been demonstrated to be a reservoir for multidrug-resistant organisms and should be mechanically disinfected between uses [<a href="#rid116">116</a>].</p><p>Although slightly mixed, studies on <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing generally support its efficacy. In a meta-analysis of two controlled trials and 10 observational studies of ICU patients, daily chlorhexidine bathing was associated with a decrease in health care-associated bloodstream infections compared with soap and water or no bath (odds ratio [OR] 0.44, 95% CI 0.33-0.59) [<a href="#rid103">103</a>]. Similarly, in a subsequent randomized trial that included over 7000 patients in ICUs and bone marrow transplant units, there was a 28 percent reduction in the rate of hospital-acquired bloodstream infections (4.8 versus 6.6 cases per 1000 patient-days, respectively) [<a href="#rid104">104</a>]. The reduction in bloodstream infections with chlorhexidine was greatest for coagulase-negative staphylococci and fungal infections. Some studies suggest a trend towards reduced gram-negative infections [<a href="#rid117">117</a>]. Given the broad in vitro activity of chlorhexidine, and lack of significant adverse impacts associated with chlorhexidine bathing, it could be used as a measure to contain the spread of currently endemic ICU multi-drug resistant organisms.</p><p><a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">Chlorhexidine</a> bathing has also been studied in critically ill pediatric patients. In a large trial including more than 6000 pediatric ICU patients older than two months, there was a nonsignificant reduction in the incidence of bacteremia with daily chlorhexidine bathing compared with standard bathing practices in the intention-to-treat analysis (3.5 versus 4.9 per 1000 days) [<a href="#rid110">110</a>]. In the per-protocol population, the incidence of bacteremia was lower among patients who received chlorhexidine bathing (3.3 versus 4.9 events per 1000 days, adjusted relative risk 0.64, 95% CI 0.42-0.98).</p><p>Although one cluster-randomized, crossover study including 9340 adults in ICUs noted that daily <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing did not demonstrate a reduced incidence of health care-associated infections, the study was underpowered to detect such differences due to the rarity of events, which limits the generalizability of the results [<a href="#rid118">118,119</a>]. A Cochrane systematic review that included this trial and seven others, comprising greater than 24,000 patients, noted reductions in rate of nosocomial infection (rate difference 1.70 fewer infections per 1000 patient-days, 95% CI 0.12-3.29) and mortality (OR 0.87, 95% CI 0.76-0.99) with chlorhexidine bathing but deemed the evidence to be of very low quality [<a href="#rid120">120</a>].</p><p>Reported adverse effects of <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing are rare and predominantly mild skin reactions [<a href="#rid103">103,110</a>]. It is also relatively inexpensive.</p><p>However, emergence of resistance to <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> is an important consideration [<a href="#rid105">105,121</a>]. In a study including two 15-bed ICUs over a four-year period, introduction of a chlorhexidine-based surface antiseptic protocol was associated with a 70 percent reduction in MRSA transmission, although transmission of strains carrying the plasmid-born <em>qacA/B </em>gene (which codes for multidrug efflux pumps and can lead to chlorhexidine resistance) was not reduced [<a href="#rid105">105</a>]. Resistance to triclosan, an ingredient in some antimicrobial soaps, has also emerged among dermal, intestinal, and environmental microorganisms, including <em>S. aureus</em> [<a href="#rid122">122,123</a>].</p><p class="headingAnchor" id="H232362736"><span class="h4">Patient bathing plus decolonization</span><span class="headingEndMark"> — </span>Although not universally recommended, decolonization with <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> and <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> is recommended by some expert guidelines, and there is growing evidence supporting this practice [<a href="#rid124">124</a>]. It is unclear whether the addition of decolonization to chlorhexidine bathing is more effective than chlorhexidine alone (except in cases of a targeted intervention to reduce <em>S. aureus</em> acquisitions and/or infections), although the addition of chlorhexidine has been demonstrated to be more effective than nasal iodophors. </p><p>Nasal decolonization with twice-daily <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> combined with daily <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing may be particularly beneficial in ICUs with high rates of <em>S. aureus </em>infections, including MRSA. In a large, multicenter trial that involved over 74,000 patients, universal decolonization with chlorhexidine and twice daily intranasal mupirocin reduced both MRSA-positive clinical cultures and bloodstream infections due to any pathogen (HRs 0.63 and 0.56 compared with baseline rates) to a greater extent than screening and isolation (HRs 0.92 and 0.99) or targeted decolonization of carriers (HRs 0.75 and 0.78) [<a href="#rid83">83</a>]. The number of patients requiring decolonization to prevent one MRSA infection or one bloodstream infection was 181 or 54, respectively. Since both chlorhexidine and mupirocin were used for decolonization, the clinical effect in this study cannot reliably be attributed to chlorhexidine or mupirocin alone. </p><p>Resistance of <em>S. aureus </em>to <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> has been well described, and varies by region [<a href="#rid125">125</a>]. Some centers have elected to substitute intranasal iodophore (eg, povidone-iodine) for mupirocin because iodophors exhibit less resistance and are often less costly [<a href="#rid126">126</a>]. However, in an open-label cluster-randomized trial in over 230 adult ICUs in 137 hospitals whose ICUs provide daily bathing to all patients, universal use of nasal iodophore was associated with an increase of <em>S. aureus</em> clinical cultures by 18 percent compared with mupirocin [<a href="#rid127">127</a>]. Based on the results of this study, we suggest that centers electing to perform universal decolonization in their ICUs choose nasal mupirocin ointment be used rather than nasal iodophors. </p><p>The use of targeted decolonization for patients with confirmed MRSA is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Targeted decolonization'</a>.)</p><p class="headingAnchor" id="H534373320"><span class="h3">Digestive and oropharyngeal decontamination</span><span class="headingEndMark"> — </span>Decontamination of the digestive and oropharyngeal tracts has been proposed as a method to reduce HAIs and mortality in critically ill patients by reducing microorganism colonization.</p><p>Decontamination methods include oropharyngeal decontamination with antiseptics (eg, <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>), selective oropharyngeal decontamination (SOD) with antibiotics, and selective digestive decontamination (SDD) with antibiotics.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oropharyngeal decontamination with antiseptics</strong> – Oral care of ventilated patients in the ICU using <a class="drug drug_general" data-topicid="9031" href="/d/drug information/9031.html" rel="external">antiseptic mouthwash</a> or gel (usually <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>) has been a common intervention in ICUs in the United States and Europe [<a href="#rid128">128</a>]. Multiple systematic reviews and meta-analyses have suggested that VAP rates may be decreased by this intervention, but when analyses were limited to double-blinded studies, VAP rates were not improved [<a href="#rid128">128-139</a>]. Due to lack of clear reduction in VAP rates and in mortality, and some data that suggest increased mortality, updated American guidelines recommend against using chlorhexidine for oral care [<a href="#rid128">128,133,134,139-143</a>]. European guidelines purposely did not issue a recommendation for this practice until more safety data become available [<a href="#rid144">144</a>]. However, as depicted below, mouth hygiene is of paramount importance among mechanically ventilated patients, and practices should be standardized and monitored. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective oral decontamination (SOD) and selective digestive decontamination (SDD)</strong> – These interventions use antibiotics instead of antiseptics to attempt to decontaminate the oropharynx (SOD) or the entire digestive tract (SDD). SOD involves applying an oral paste of nonabsorbable antibiotics (often a combination of <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>, <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, and an antifungal) to the mouths of ventilated patients. SDD involves SOD plus administration of nonabsorbable antibiotics directly into the GI tract via the stomach; in some protocols, a few doses of intravenous antibiotics are also administered.</p><p></p><p class="bulletIndent1">Modest mortality benefits have been demonstrated among ICU patients treated with SOD or SDD in the Netherlands, a region with low baseline antimicrobial resistance [<a href="#rid139">139-141,144-150</a>]. However, these interventions have not found widespread favor outside the Netherlands, since no benefit for their use has yet been observed in ICUs with moderate to high levels of antibiotic resistance [<a href="#rid139">139,141,144,145,147,151-153</a>]. In addition, there is uncertainty regarding the long-term effects of SOD and SDD on emergence of antimicrobial resistance [<a href="#rid146">146,147,152-160</a>]. European and American guidelines recommend against using SOD or SDD in countries, regions, or ICUs with high prevalence of antibiotic resistance, although they state that SOD or SDD could be considered in ICUs with low prevalence of antibiotic-resistant organisms [<a href="#rid139">139,141,144</a>]. </p><p></p><p>Basic oral hygiene using toothbrushes is recommended in all ventilated ICU patients [<a href="#rid139">139</a>]. A more detailed discussion of the impact of oropharyngeal <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>, SOD, and SDD on rates of VAP is discussed separately. (See  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Decontamination of the oropharynx and digestive tract'</a>.)</p><p class="headingAnchor" id="H353071065"><span class="h3">Surveillance</span><span class="headingEndMark"> — </span>Surveillance for infections with multidrug-resistant bacteria within the institution as a whole and within specific units is critical for the early identification and control of epidemic outbreaks and endemic increases of resistant bacteria. The incidence and prevalence of isolation of multidrug-resistant bacteria (eg, MRSA, VRE, and carbapenem-resistant gram-negative bacilli) should be monitored, and these data should be disseminated to nurses and clinicians who work in the ICU through a form that is easy to interpret. It is useful to compare data from different time periods for one ICU and to compare different units within the same hospital. The United States National Healthcare Safety Network System also provides comparisons of rates among participating hospitals [<a href="#rid22">22</a>]. Comparing rates among different institutions helps to identify hospitals or units where problems persist and can help to gauge the efficacy of interventions aimed at controlling rates of endemic and epidemic resistant organisms. (See  <a class="medical medical_review" href="/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control", section on 'Surveillance cultures'</a> and  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p>Positive surveillance culture results should be coupled with effective flagging systems and established routes of communication inside the facility and between neighboring facilities in order to be successful [<a href="#rid161">161</a>]. In theory, this measure can reduce patient-to-patient transmission rates.</p><p>Active surveillance cultures, or screening patients for asymptomatic colonization with resistant organisms, is widely performed but may not be as effective as universal decolonization at controlling the spread of MRSA. In a large multicenter trial described above, universal <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing and nasal <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> reduced rates of MRSA clinical isolates and bloodstream infections from any pathogen to a greater extent than did screening for MRSA and isolating carriers [<a href="#rid83">83</a>] (see <a class="local">'Patient bathing/decolonization'</a> above). This study did not evaluate active screening for other drug-resistant organisms, such as VRE. (See  <a class="medical medical_review" href="/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control", section on 'Surveillance cultures'</a>.)</p><p>Prior to this study, the efficacy of universal active surveillance cultures for MRSA was uncertain, as illustrated by the following studies with conflicting conclusions [<a href="#rid162">162-165</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cluster-randomized trial involving more than 9000 patients admitted to 18 intensive care units, use of MRSA surveillance cultures and expanded use of barrier precautions (universal glove precautions while awaiting active surveillance culture results) were not effective in reducing transmission of MRSA compared with existing practice [<a href="#rid164">164</a>]. This finding was surprising given that surveillance cultures identified a sizable subgroup of colonized patients who were not otherwise recognized. The authors hypothesized that additional interventions such as antiseptic bathing and improved environmental decontamination may be needed. Limitations of the study included the long turn-around time of the active surveillance cultures and omission of gowns as part of the barrier precautions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Veterans Affairs system-wide quality improvement initiative including nearly two million patients in 150 hospitals, a MRSA "bundle" program (including universal MRSA surveillance, contact precautions for colonized or infected patients, hand hygiene, and institutional culture change) was implemented [<a href="#rid165">165</a>]. This program was temporally associated with a reduction in the rate of health care-associated MRSA infection in ICUs by 62 percent (from 1.64 to 0.62 infections per 1000 patient-days) and general units by 45 percent (from 0.47 to 0.26 infections per 1000 patient-days). However, as this study did not include control groups, it was not possible to determine whether MRSA surveillance was causally related to the observed drop in rates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A mathematical model demonstrated that the universal screen and isolate strategy could have contributed only marginally to the reduction in infections, since transmission rates before bundle implementation were already low and most patients with MRSA colonization were already colonized at admission [<a href="#rid166">166</a>].</p><p></p><p>However, there are other pathogens (such as VRE and carbapenem-resistant Enterobacterales) for which active surveillance may continue to be an important measure in the efforts to contain the spread of these organisms in health care settings [<a href="#rid98">98</a>]. Moreover, since decolonization may not be practical or effective for these pathogens, active surveillance and strict contact isolation for carriers is still important for limiting spread [<a href="#rid167">167</a>]. Screening for asymptomatic carriage of <em>C. difficile</em> is gaining interest but data are not yet conclusive [<a href="#rid168">168</a>]. There are no reliable surveillance techniques to detect carriage of <em>P. aeruginosa</em>;<em> </em>however, for <em>A. baumannii</em>, different techniques have been used to detect carriage [<a href="#rid169">169-171</a>]. (See  <a class="medical medical_review" href="/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control", section on 'Surveillance cultures'</a>.)</p><p class="headingAnchor" id="H353072463"><span class="h3">Device-specific strategies</span><span class="headingEndMark"> — </span>Preventing infections and decreasing the length of hospital stay of patients will decrease antimicrobial utilization and decrease the risk of becoming infected or colonized with resistant bacteria. Limiting unnecessary use of central venous catheter, bladder catheter, and endotracheal intubation decreases infection rates, decreases antibiotic use, and decreases selective antibiotic pressure on resident bacteria. Clinicians should assess on a daily basis the need to keep each of these invasive devices in place [<a href="#rid172">172</a>].</p><p>In addition, as many of the multidrug-resistant infections in the ICU are associated with indwelling devices, specific strategies for placement and care of such devices, as well as additional adjunctive measures, are effective in reducing the risk of catheter-associated urinary tract infections (CAUTIs), VAP  (<a class="graphic graphic_table graphicRef69916" href="/d/graphic/69916.html" rel="external">table 1</a>), and intravascular catheter-related bloodstream infection  (<a class="graphic graphic_table graphicRef75251" href="/d/graphic/75251.html" rel="external">table 2</a>). These strategies are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8090.html" rel="external">"Placement and management of urinary bladder catheters in adults"</a> and  <a class="medical medical_review" href="/d/html/8095.html" rel="external">"Complications of urinary bladder catheters and preventive strategies", section on 'Prevention of complications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Prevention'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p></p><p class="headingAnchor" id="H107535091"><span class="h3">Environmental cleaning</span><span class="headingEndMark"> — </span>Environmental cleaning, disinfection, and sterilization are basic and important measures used to prevent or reduce infections in the intensive care unit, as in the rest of the hospital environment. Innovative but as yet experimental techniques for environmental decontamination include ultraviolet light sterilization lamps, hydrogen-peroxide vapor decontamination devices, and other technologies, which might contribute to future attempts at reducing colonization pressure. However, these new technologies will not replace the necessity of proper manual "terminal" cleaning that should be established by a written protocol in every ICU, and adherence to the protocol must be regularly monitored. (See  <a class="medical medical_review" href="/d/html/101613.html" rel="external">"Infection prevention: General principles", section on 'Health care environment: Cleaning and disinfection'</a>.)</p><p class="headingAnchor" id="H426464"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors contributing to ICU infections</strong> – Infections are especially frequent in intensive care units (ICUs) because the patients are likely to have chronic illnesses and acute physiologic derangements, indwelling catheterization is common, and multidrug-resistant pathogens that are difficult to eradicate are isolated with increasing frequency due to enhanced selective antimicrobial pressure and enhanced colonization pressure. (See <a class="local">'Epidemiology of nosocomial infections'</a> above and <a class="local">'Epidemiology of antibiotic-resistant organisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multi-drug resistant organisms</strong> – The most common multi- and extensively drug-resistant pathogens isolated in ICUs include methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter baumannii</em>, and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. Carbapenem-resistant Enterobacterales are also increasing in prevalence. <em>Clostridioides difficile</em>, <em>Candida auris</em>, and intrinsically carbapenem-resistant nonglucose fermenting gram-negatives (eg, <em>Stenotrophomonas maltophilia</em>) are an emerging threat. (See <a class="local">'Epidemiology of antibiotic-resistant organisms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors for multi-drug resistant organisms</strong> – Comorbid conditions, long hospital courses, frequent contact with health care personnel, indwelling catheterization, and receipt of antimicrobial therapy all increase the risk of colonization and infection with multidrug-resistant pathogens. Infections with such organisms are associated with increased mortality, length of stay, and hospital costs. (See <a class="local">'Risk factors'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection control</strong> – Good hand hygiene compliance, contact precautions for patients who harbor epidemiologically relevant drug-resistant organisms, and minimizing unnecessary hospitalization and interventions are critical for preventing infection and the spread of resistant organisms in the ICU. Adequate and standardized approaches to environmental cleaning and disinfection is an additional established measure to contain the spread of multidrug-resistant organisms. More intensive infection control interventions to reduce colonization pressure include cohorting with dedicated staff, <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing, selective decontamination, active surveillance for certain pathogens, and reduction of catheterization utilization. (See <a class="local">'Infection control measures'</a> above and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic stewardship</strong> – Restricted and judicious antibiotic utilization, often implemented as part of a global institutional antimicrobial stewardship program, can decrease selective pressure that promotes emergence of resistant bacterial strains. Infection control measures such as hand hygiene prevent the spread of multidrug-resistant organisms. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">Chlorhexidine</a><strong> bathing</strong> <strong>and nasal decolonization </strong>– For all patients in an ICU, we suggest daily chlorhexidine bathing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Daily chlorhexidine bathing decreases the risk of colonization and infection with drug-resistant and other organisms and is associated with minimal adverse effects. Additionally, it may be more effective in controlling certain infections than an active surveillance policy. (See <a class="local">'Prevention'</a> above.) </p><p></p><p class="bulletIndent1">For hospitals that elect to add nasal decolonization to daily <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing in their ICUs, we suggest nasal <a class="drug drug_general" data-topicid="9668" href="/d/drug information/9668.html" rel="external">mupirocin</a> rather than nasal iodophors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Nasal decolonization with mupirocin combined with daily chlorhexidine bathing may be particularly beneficial in ICUs with high rates of <em>S. aureus </em>infections, including MRSA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of infections in the ICU</strong> – The most common infections in the ICU are those associated with indwelling devices, namely intravascular catheter-related bloodstream infection, ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infection. Apart from minimizing their use, certain strategies regarding placement and care of indwelling devices can decrease the risk of infection  (<a class="graphic graphic_table graphicRef75251" href="/d/graphic/75251.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef69916" href="/d/graphic/69916.html" rel="external">table 1</a>). The epidemiology, management, and prevention of these infections are discussed in detail elsewhere.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults"</a> and  <a class="medical medical_review" href="/d/html/8095.html" rel="external">"Complications of urinary bladder catheters and preventive strategies"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a> and  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997; 11:479.</a></li><li><a class="nounderline abstract_t">Buetti N, Marschall J, Drees M, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022; 43:553.</a></li><li><a class="nounderline abstract_t">Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S31.</a></li><li><a class="nounderline abstract_t">Lo E, Nicolle L, Classen D, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S41.</a></li><li><a class="nounderline abstract_t">Chenoweth CE, Saint S. Urinary tract infections. Infect Dis Clin North Am 2011; 25:103.</a></li><li><a class="nounderline abstract_t">Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents 2001; 17:299.</a></li><li><a class="nounderline abstract_t">Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991; 91:65S.</a></li><li><a class="nounderline abstract_t">Bryan CS, Reynolds KL. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. J Urol 1984; 132:494.</a></li><li><a class="nounderline abstract_t">Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis 1983; 148:57.</a></li><li><a class="nounderline abstract_t">Paradisi F, Corti G, Mangani V. Urosepsis in the critical care unit. Crit Care Clin 1998; 14:165.</a></li><li><a class="nounderline abstract_t">Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001; 7:342.</a></li><li><a class="nounderline abstract_t">Wagenlehner FM, Naber KG. Hospital-acquired urinary tract infections. J Hosp Infect 2000; 46:171.</a></li><li><a class="nounderline abstract_t">Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med 2000; 160:678.</a></li><li><a class="nounderline abstract_t">Nicolle LE. The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria. Pathogens 2016; 5.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention (CDC). 2020 National and State HAI progress report SIR data - acute care hospitals. https://www.cdc.gov/hai/data/portal/progress-report.html#Tables (Accessed on August 07, 2022).</li><li class="breakAll">United STates Centers for Disease Control and Prevention (CDC). National Healthcare Safety Network (NHSN). Ventilator-associated event (VAE). https://www.cdc.gov/nhsn/pdfs/pscmanual/10-vae_final.pdf (Accessed on August 07, 2022).</li><li><a class="nounderline abstract_t">Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145:582.</a></li><li><a class="nounderline abstract_t">Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36:627.</a></li><li><a class="nounderline abstract_t">Hynes-Gay P, Lalla P, Leo M, et al. Understanding sepsis: from SIRS to septic shock. Dynamics 2002; 13:17.</a></li><li><a class="nounderline abstract_t">Kaye KS, Marchaim D, Smialowicz C, Bentley L. Suction regulators: a potential vector for hospital-acquired pathogens. Infect Control Hosp Epidemiol 2010; 31:772.</a></li><li><a class="nounderline abstract_t">National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429.</a></li><li><a class="nounderline abstract_t">Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.</a></li><li><a class="nounderline abstract_t">Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Crit Care 2009; 13:106.</a></li><li><a class="nounderline abstract_t">Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813.</a></li><li><a class="nounderline abstract_t">Bonten MJ. Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria. Crit Care 2012; 16:142.</a></li><li><a class="nounderline abstract_t">Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 2020; 41:1.</a></li><li><a class="nounderline abstract_t">Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1.</a></li><li><a class="nounderline abstract_t">Goldenberg SD, Dodgson AR, Barlow G, et al. Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK). Adv Ther 2022; 39:3602.</a></li><li><a class="nounderline abstract_t">Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140:1643.</a></li><li><a class="nounderline abstract_t">Zilberberg MD, Shorr AF. Fungal infections in the ICU. Infect Dis Clin North Am 2009; 23:625.</a></li><li><a class="nounderline abstract_t">Baquero F, Negri MC, Morosini MI, Blázquez J. Antibiotic-selective environments. Clin Infect Dis 1998; 27 Suppl 1:S5.</a></li><li><a class="nounderline abstract_t">Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of methicillin-resistant Staphylococcus aureus colonization at admission in the general ICU Setting: a meta-analysis of published studies. Crit Care Med 2014; 42:433.</a></li><li><a class="nounderline abstract_t">Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323.</a></li><li><a class="nounderline abstract_t">Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682.</a></li><li><a class="nounderline abstract_t">Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000; 14:293.</a></li><li><a class="nounderline abstract_t">Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834.</a></li><li><a class="nounderline abstract_t">Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 1991; 91:179S.</a></li><li><a class="nounderline abstract_t">Kaye KS, Cosgrove S, Harris A, et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45:2628.</a></li><li><a class="nounderline abstract_t">Ang H, Sun X. Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: A meta-analysis. Int J Nurs Pract 2018; 24:e12644.</a></li><li><a class="nounderline abstract_t">Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817.</a></li><li><a class="nounderline abstract_t">Trouillet JL, Vuagnat A, Combes A, et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34:1047.</a></li><li><a class="nounderline abstract_t">Armand-Lefèvre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57:1488.</a></li><li><a class="nounderline abstract_t">Carmeli Y, Lidji SK, Shabtai E, et al. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 2011; 70:367.</a></li><li><a class="nounderline abstract_t">Dortch MJ, Fleming SB, Kauffmann RM, et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt) 2011; 12:15.</a></li><li><a class="nounderline abstract_t">Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28:3456.</a></li><li><a class="nounderline abstract_t">Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA 1996; 275:234.</a></li><li><a class="nounderline abstract_t">Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462.</a></li><li><a class="nounderline abstract_t">Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412.</a></li><li class="breakAll">Cosgrove S, Qi Y, Kaye K, et al. The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia (SAB) on Patient (Pt) Outcomes: Mortality, Length of Stay (LOS), and Hospital Charge (HC), 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2001.</li><li class="breakAll">Engemann J, Carmeli Y, Bronstein M, et al. Outcomes Attributable to Methicillin Resistance (MR) among Patients with Staphylococcus aureus (SA) Surgical Site Infections (SSI): Hospital Charges, Hospital Days and Mortality, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2001.</li><li><a class="nounderline abstract_t">Neidell MJ, Cohen B, Furuya Y, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55:807.</a></li><li><a class="nounderline abstract_t">Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012; 40:983.</a></li><li><a class="nounderline abstract_t">Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851.</a></li><li><a class="nounderline abstract_t">Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010; 362:1804.</a></li><li><a class="nounderline abstract_t">Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298.</a></li><li><a class="nounderline abstract_t">Kollef MH. Antimicrobial therapy of ventilator-associated pneumonia: how to select an appropriate drug regimen. Chest 1999; 115:8.</a></li><li><a class="nounderline abstract_t">Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237.</a></li><li><a class="nounderline abstract_t">Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861.</a></li><li><a class="nounderline abstract_t">Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.</a></li><li><a class="nounderline abstract_t">Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484.</a></li><li><a class="nounderline abstract_t">Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104:24S.</a></li><li><a class="nounderline abstract_t">Gleason TG, Crabtree TD, Pelletier SJ, et al. Prediction of poorer prognosis by infection with antibiotic-resistant gram-positive cocci than by infection with antibiotic-sensitive strains. Arch Surg 1999; 134:1033.</a></li><li><a class="nounderline abstract_t">Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20:408.</a></li><li><a class="nounderline abstract_t">Menon KV, Whiteley MS, Burden P, Galland RB. Surgical patients with methicillin resistant staphylococcus aureus infection: an analysis of outcome using P-POSSUM. J R Coll Surg Edinb 1999; 44:161.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.</a></li><li><a class="nounderline abstract_t">Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010; 54:5099.</a></li><li><a class="nounderline abstract_t">Marchaim D, Kaye KS, Fowler VG, et al. Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16:747.</a></li><li><a class="nounderline abstract_t">Teerawattanapong N, Kengkla K, Dilokthornsakul P, et al. Prevention and Control of Multidrug-Resistant Gram-Negative Bacteria in Adult Intensive Care Units: A Systematic Review and Network Meta-analysis. Clin Infect Dis 2017; 64:S51.</a></li><li><a class="nounderline abstract_t">Strich JR, Palmore TN. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit. Infect Dis Clin North Am 2017; 31:535.</a></li><li><a class="nounderline abstract_t">Doernberg SB, Chambers HF. Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infect Dis Clin North Am 2017; 31:513.</a></li><li><a class="nounderline abstract_t">Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159.</a></li><li><a class="nounderline abstract_t">Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.</a></li><li><a class="nounderline abstract_t">Classen DC, Burke JP, Wenzel RP. Infectious diseases consultation: impact on outcomes for hospitalized patients and results of a preliminary study. Clin Infect Dis 1997; 24:468.</a></li><li><a class="nounderline abstract_t">Lundberg J, Nettleman MD, Costigan M, et al. Staphylococcus aureus bacteremia: the cost-effectiveness of long-term therapy associated with infectious diseases consultation. Clin Perform Qual Health Care 1998; 6:9.</a></li><li><a class="nounderline abstract_t">Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother 2010; 65:1062.</a></li><li><a class="nounderline abstract_t">Lindsay PJ, Rohailla S, Taggart LR, et al. Antimicrobial Stewardship and Intensive Care Unit Mortality: A Systematic Review. Clin Infect Dis 2019; 68:748.</a></li><li><a class="nounderline abstract_t">Rice LB. Controlling antibiotic resistance in the ICU: different bacteria, different strategies. Cleve Clin J Med 2003; 70:793.</a></li><li><a class="nounderline abstract_t">Pechère JC. Rotating antibiotics in the intensive care unit: feasible, apparently beneficial, but questions remain. Crit Care 2002; 6:9.</a></li><li><a class="nounderline abstract_t">Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344:1427.</a></li><li><a class="nounderline abstract_t">Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745.</a></li><li><a class="nounderline abstract_t">Haley RW, Cushion NB, Tenover FC, et al. Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis 1995; 171:614.</a></li><li><a class="nounderline abstract_t">Dembry LM, Uzokwe K, Zervos MJ. Control of endemic glycopeptide-resistant enterococci. Infect Control Hosp Epidemiol 1996; 17:286.</a></li><li><a class="nounderline abstract_t">Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013; 368:2255.</a></li><li><a class="nounderline abstract_t">Lorente L. Does chlorhexidine-impregnated dressing reduce the risk of catheter-related bloodstream infection in all vascular access? Crit Care Med 2015; 43:e50.</a></li><li><a class="nounderline abstract_t">Rutala WA, Gergen MF, Weber DJ. Room decontamination with UV radiation. Infect Control Hosp Epidemiol 2010; 31:1025.</a></li><li><a class="nounderline abstract_t">Widmer AF. Replace hand washing with use of a waterless alcohol hand rub? Clin Infect Dis 2000; 31:136.</a></li><li><a class="nounderline abstract_t">McNeil SA, Foster CL, Hedderwick SA, Kauffman CA. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis 2001; 32:367.</a></li><li><a class="nounderline abstract_t">Lastinger LM, Alvarez CR, Kofman A, et al. Continued increases in the incidence of healthcare-associated infection (HAI) during the second year of the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 2023; 44:997.</a></li><li><a class="nounderline abstract_t">Wright MO, Hebden JN, Harris AD, et al. Aggressive control measures for resistant Acinetobacter baumannii and the impact on acquisition of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004; 25:167.</a></li><li><a class="nounderline abstract_t">Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control 2006; 34:476.</a></li><li><a class="nounderline abstract_t">Yin J, Schweizer ML, Herwaldt LA, et al. Benefits of universal gloving on hospital-acquired infections in acute care pediatric units. Pediatrics 2013; 131:e1515.</a></li><li><a class="nounderline abstract_t">Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA 2013; 310:1571.</a></li><li><a class="nounderline abstract_t">Harris AD, Morgan DJ, Pineles L, et al. Acquisition of Antibiotic-Resistant Gram-negative Bacteria in the Benefits of Universal Glove and Gown (BUGG) Cluster Randomized Trial. Clin Infect Dis 2021; 72:431.</a></li><li><a class="nounderline abstract_t">Morgan DJ, Dubberke ER, Hink T, et al. The Impact of Universal Glove and Gown Use on Clostridioides Difficile Acquisition: A Cluster-Randomized Trial. Clin Infect Dis 2023; 76:e1202.</a></li><li><a class="nounderline abstract_t">Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003; 290:1899.</a></li><li><a class="nounderline abstract_t">Morgan DJ, Diekema DJ, Sepkowitz K, Perencevich EN. Adverse outcomes associated with Contact Precautions: a review of the literature. Am J Infect Control 2009; 37:85.</a></li><li><a class="nounderline abstract_t">Dhar S, Marchaim D, Tansek R, et al. Contact precautions: more is not necessarily better. Infect Control Hosp Epidemiol 2014; 35:213.</a></li><li><a class="nounderline abstract_t">Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848.</a></li><li><a class="nounderline abstract_t">Marchaim D, Perez F, Lee J, et al. "Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa. Am J Infect Control 2012; 40:830.</a></li><li><a class="nounderline abstract_t">Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37:1858.</a></li><li><a class="nounderline abstract_t">Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009; 30:1031.</a></li><li><a class="nounderline abstract_t">Borer A, Gilad J, Porat N, et al. Impact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unit. J Hosp Infect 2007; 67:149.</a></li><li><a class="nounderline abstract_t">O'Horo JC, Silva GL, Munoz-Price LS, Safdar N. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis. Infect Control Hosp Epidemiol 2012; 33:257.</a></li><li><a class="nounderline abstract_t">Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.</a></li><li><a class="nounderline abstract_t">Batra R, Cooper BS, Whiteley C, et al. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2010; 50:210.</a></li><li><a class="nounderline abstract_t">Montecalvo MA, McKenna D, Yarrish R, et al. Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability. Am J Med 2012; 125:505.</a></li><li><a class="nounderline abstract_t">Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167:2073.</a></li><li><a class="nounderline abstract_t">Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006; 166:306.</a></li><li><a class="nounderline abstract_t">Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46:274.</a></li><li><a class="nounderline abstract_t">Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 2013; 381:1099.</a></li><li><a class="nounderline abstract_t">Munoz-Price LS, Dezfulian C, Wyckoff M, et al. Effectiveness of stepwise interventions targeted to decrease central catheter-associated bloodstream infections. Crit Care Med 2012; 40:1464.</a></li><li><a class="nounderline abstract_t">Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014; 14:31.</a></li><li><a class="nounderline abstract_t">Huang SS, Septimus E, Hayden MK, et al. Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial. Lancet Infect Dis 2016; 16:70.</a></li><li><a class="nounderline abstract_t">Dicks KV, Lofgren E, Lewis SS, et al. A Multicenter Pragmatic Interrupted Time Series Analysis of Chlorhexidine Gluconate Bathing in Community Hospital Intensive Care Units. Infect Control Hosp Epidemiol 2016; 37:791.</a></li><li><a class="nounderline abstract_t">Sinha A, Sazawal S, Pradhan A, et al. Chlorhexidine skin or cord care for prevention of mortality and infections in neonates. Cochrane Database Syst Rev 2015; :CD007835.</a></li><li><a class="nounderline abstract_t">Marchaim D, Taylor AR, Hayakawa K, et al. Hospital bath basins are frequently contaminated with multidrug-resistant human pathogens. Am J Infect Control 2012; 40:562.</a></li><li><a class="nounderline abstract_t">Patel A, Parikh P, Dunn AN, et al. Effectiveness of daily chlorhexidine bathing for reducing gram-negative infections: A meta-analysis. Infect Control Hosp Epidemiol 2019; 40:392.</a></li><li><a class="nounderline abstract_t">Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA 2015; 313:369.</a></li><li><a class="nounderline abstract_t">Pittet D, Angus DC. Daily chlorhexidine bathing for critically ill patients: a note of caution. JAMA 2015; 313:365.</a></li><li><a class="nounderline abstract_t">Lewis SR, Schofield-Robinson OJ, Rhodes S, Smith AF. Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection. Cochrane Database Syst Rev 2019; 8:CD012248.</a></li><li><a class="nounderline abstract_t">Lee AS, Macedo-Vinas M, François P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52:1422.</a></li><li><a class="nounderline abstract_t">Yazdankhah SP, Scheie AA, Høiby EA, et al. Triclosan and antimicrobial resistance in bacteria: an overview. Microb Drug Resist 2006; 12:83.</a></li><li><a class="nounderline abstract_t">Suller MT, Russell AD. Triclosan and antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 2000; 46:11.</a></li><li class="breakAll">Universal ICU Decolonization: An Enhanced Protocol https://www.ahrq.gov/sites/default/files/publications/files/universalicu.pdf (Accessed on August 30, 2019).</li><li><a class="nounderline abstract_t">Dadashi M, Hajikhani B, Darban-Sarokhalil D, et al. Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis. J Glob Antimicrob Resist 2020; 20:238.</a></li><li><a class="nounderline abstract_t">Lepelletier D, Maillard JY, Pozzetto B, Simon A. Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Huang SS, Septimus EJ, Kleinman K, et al. Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial. JAMA 2023; 330:1337.</a></li><li><a class="nounderline abstract_t">Dale CM, Rose L, Carbone S, et al. Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial. Intensive Care Med 2021; 47:1295.</a></li><li><a class="nounderline abstract_t">Dai W, Lin Y, Yang X, et al. Meta-Analysis of the Efficacy and Safety of Chlorhexidine for Ventilator-Associated Pneumonia Prevention in Mechanically Ventilated Patients. Evid Based Complement Alternat Med 2022; 2022:5311034.</a></li><li><a class="nounderline abstract_t">Cruz JC, Martins CK, Piassi JEV, et al. Does chlorhexidine reduce the incidence of ventilator-associated pneumonia in ICU patients? A systematic review and meta-analysis. Med Intensiva (Engl Ed) 2023; 47:437.</a></li><li><a class="nounderline abstract_t">Zhao T, Wu X, Zhang Q, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev 2020; 12:CD008367.</a></li><li><a class="nounderline abstract_t">Hua F, Xie H, Worthington HV, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev 2016; 10:CD008367.</a></li><li><a class="nounderline abstract_t">Lee S, Lighvan NL, McCredie V, et al. Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis. Respir Care 2019; 64:337.</a></li><li><a class="nounderline abstract_t">Klompas M, Speck K, Howell MD, et al. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med 2014; 174:751.</a></li><li><a class="nounderline abstract_t">Labeau SO, Van de Vyver K, Brusselaers N, et al. Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis 2011; 11:845.</a></li><li><a class="nounderline abstract_t">Vieira PC, de Oliveira RB, da Silva Mendonça TM. Should oral chlorhexidine remain in ventilator-associated pneumonia prevention bundles? Med Intensiva (Engl Ed) 2022; 46:259.</a></li><li><a class="nounderline abstract_t">Liang S, Zhang X, Hu Y, et al. Association between perioperative chlorhexidine oral care and postoperative pneumonia in non-cardiac surgical patients: A systematic review and meta-analysis. Surgery 2021; 170:1418.</a></li><li><a class="nounderline abstract_t">Tantipong H, Morkchareonpong C, Jaiyindee S, Thamlikitkul V. Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2008; 29:131.</a></li><li><a class="nounderline abstract_t">Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022; 43:687.</a></li><li><a class="nounderline abstract_t">Price R, MacLennan G, Glen J, SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ 2014; 348:g2197.</a></li><li><a class="nounderline abstract_t">Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35:915.</a></li><li><a class="nounderline abstract_t">Klompas M, Li L, Kleinman K, et al. Associations Between Ventilator Bundle Components and Outcomes. JAMA Intern Med 2016; 176:1277.</a></li><li><a class="nounderline abstract_t">Deschepper M, Waegeman W, Eeckloo K, et al. Effects of chlorhexidine gluconate oral care on hospital mortality: a hospital-wide, observational cohort study. Intensive Care Med 2018; 44:1017.</a></li><li><a class="nounderline abstract_t">Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360:20.</a></li><li><a class="nounderline abstract_t">de Smet AM, Kluytmans JA, Blok HE, et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011; 11:372.</a></li><li><a class="nounderline abstract_t">Bonten M. Selective Decontamination of the Digestive Tract: An Answer at Last? JAMA 2022; 328:2310.</a></li><li><a class="nounderline abstract_t">Minozzi S, Pifferi S, Brazzi L, et al. Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation. Cochrane Database Syst Rev 2021; 1:CD000022.</a></li><li><a class="nounderline abstract_t">Bos LD, Stips C, Schouten LR, et al. Selective decontamination of the digestive tract halves the prevalence of ventilator-associated pneumonia compared to selective oral decontamination. Intensive Care Med 2017; 43:1535.</a></li><li><a class="nounderline abstract_t">Plantinga NL, de Smet AMGA, Oostdijk EAN, et al. Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: individual patient data meta-analysis. Clin Microbiol Infect 2018; 24:505.</a></li><li><a class="nounderline abstract_t">Bonten MJ. Healthcare epidemiology: Ventilator-associated pneumonia: preventing the inevitable. Clin Infect Dis 2011; 52:115.</a></li><li><a class="nounderline abstract_t">Reis Miranda D, Citerio G, Perner A, et al. Use of selective digestive tract decontamination in European intensive cares: the ifs and whys. Minerva Anestesiol 2015; 81:734.</a></li><li><a class="nounderline abstract_t">Wittekamp BH, Plantinga NL, Cooper BS, et al. Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial. JAMA 2018; 320:2087.</a></li><li><a class="nounderline abstract_t">Wunderink RG. Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med 2010; 181:426.</a></li><li><a class="nounderline abstract_t">Oostdijk EA, de Smet AM, Blok HE, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010; 181:452.</a></li><li><a class="nounderline abstract_t">Kollef MH, Micek ST. Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. JAMA 2014; 312:1403.</a></li><li><a class="nounderline abstract_t">van der Meer JW, Vandenbroucke-Grauls CM. Resistance to selective decontamination: the jury is still out. Lancet Infect Dis 2013; 13:282.</a></li><li><a class="nounderline abstract_t">Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 2014; 312:1429.</a></li><li><a class="nounderline abstract_t">SuDDICU Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Myburgh JA, Seppelt IM, et al. Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA 2022; 328:1911.</a></li><li><a class="nounderline abstract_t">Hammond NE, Myburgh J, Seppelt I, et al. Association Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation: A Systematic Review and Meta-analysis. JAMA 2022; 328:1922.</a></li><li><a class="nounderline abstract_t">Marchaim D, Chopra T, Bogan C, et al. The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. Am J Infect Control 2012; 40:760.</a></li><li><a class="nounderline abstract_t">Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299:1149.</a></li><li><a class="nounderline abstract_t">Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409.</a></li><li><a class="nounderline abstract_t">Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011; 364:1407.</a></li><li><a class="nounderline abstract_t">Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011; 364:1419.</a></li><li><a class="nounderline abstract_t">Gurieva T, Bootsma MC, Bonten MJ. Successful Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections revisited. Clin Infect Dis 2012; 54:1618.</a></li><li><a class="nounderline abstract_t">Siddiqui AH, Harris AD, Hebden J, et al. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002; 30:40.</a></li><li><a class="nounderline abstract_t">Grigoras CA, Zervou FN, Zacharioudakis IM, et al. Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data. PLoS One 2016; 11:e0156577.</a></li><li><a class="nounderline abstract_t">Marchaim D, Navon-Venezia S, Schwartz D, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol 2007; 45:1551.</a></li><li><a class="nounderline abstract_t">Nutman A, Temkin E, Lellouche J, et al. Detecting carbapenem-resistant Acinetobacter baumannii (CRAB) carriage: Which body site should be cultured? Infect Control Hosp Epidemiol 2020; 41:965.</a></li><li><a class="nounderline abstract_t">Doi Y, Onuoha EO, Adams-Haduch JM, et al. Screening for Acinetobacter baumannii colonization by use of sponges. J Clin Microbiol 2011; 49:154.</a></li><li><a class="nounderline abstract_t">Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725.</a></li></ol></div><div id="topicVersionRevision">Topic 3810 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187957" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Magnitude and prevention of nosocomial infections in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35437133" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840087" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Strategies to prevent ventilator-associated pneumonia in acute care hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840088" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Strategies to prevent catheter-associated urinary tract infections in acute care hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315996" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11295412" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Catheter-associated urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928194" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6471184" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6350488" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Urinary tract etiology of bloodstream infections in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9561812" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Urosepsis in the critical care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294737" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Engineering out the risk for infection with urinary catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073725" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hospital-acquired urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724054" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104571" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104571" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104571" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043340" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Device-associated nosocomial infections in 55 intensive care units of 8 developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18834725" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11951322" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Understanding sepsis: from SIRS to septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20486854" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Suction regulators: a potential vector for hospital-acquired pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11114613" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18947320" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19216721" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070961" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical and economic impact of common multidrug-resistant gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22849650" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31767041" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035777" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35701725" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology, Outcomes and Resource Utilisation in Patients with Carbapenem Non-susceptible Gram-Negative Bacteria in the UK: A Retrospective, Observational Study (CARBAR UK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147824" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clostridium difficile in the ICU: the struggle continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665087" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fungal infections in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9710666" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antibiotic-selective environments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145849" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The prevalence and significance of methicillin-resistant Staphylococcus aureus colonization at admission in the general ICU Setting: a meta-analysis of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952319" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : International study of the prevalence and outcomes of infection in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622043" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10829257" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044132" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928162" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Epidemiology and control of nosocomial infections in adult intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502540" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29575345" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759550" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914992" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318796" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683268" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091186" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11057801" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604178" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027448" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498961" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498961" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498961" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22700828" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440526" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733044" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463340" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hospital-acquired infections due to gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182841" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antibiotic resistance in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925056" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antimicrobial therapy of ventilator-associated pneumonia: how to select an appropriate drug regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696123" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696442" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625125" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11578151" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684655" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522842" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prediction of poorer prognosis by infection with antibiotic-resistant gram-positive cocci than by infection with antibiotic-sensitive strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10395142" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372484" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Surgical patients with methicillin resistant staphylococcus aureus infection: an analysis of outcome using P-POSSUM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173215" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837757" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19723135" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475791" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention and Control of Multidrug-Resistant Gram-Negative Bacteria in Adult Intensive Care Units: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687211" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687210" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antimicrobial Stewardship Approaches in the Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173212" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770144" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114202" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Infectious diseases consultation: impact on outcomes for hospitalized patients and results of a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10177050" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Staphylococcus aureus bacteremia: the cost-effectiveness of long-term therapy associated with infectious diseases consultation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215130" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982376" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Antimicrobial Stewardship and Intensive Care Unit Mortality: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14518574" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Controlling antibiotic resistance in the ICU: different bacteria, different strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940258" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rotating antibiotics in the intensive care unit: feasible, apparently beneficial, but questions remain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346807" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Control of vancomycin-resistant enterococcus in health care facilities in a region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568647" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876608" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8727617" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Control of endemic glycopeptide-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718152" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Targeted versus universal decolonization to prevent ICU infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599496" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Does chlorhexidine-impregnated dressing reduce the risk of catheter-related bloodstream infection in all vascular access?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804377" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Room decontamination with UV radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913411" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Replace hand washing with use of a waterless alcohol hand rub?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170943" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35591782" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Continued increases in the incidence of healthcare-associated infection (HAI) during the second year of the coronavirus disease 2019 (COVID-19) pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14994945" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aggressive control measures for resistant Acinetobacter baumannii and the impact on acquisition of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015152" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610206" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Benefits of universal gloving on hospital-acquired infections in acute care pediatric units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097234" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31970393" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acquisition of Antibiotic-Resistant Gram-negative Bacteria in the Benefits of Universal Glove and Gown (BUGG) Cluster Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35776131" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Impact of Universal Glove and Gown Use on Clostridioides Difficile Acquisition: A Cluster-Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14532319" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Safety of patients isolated for infection control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249637" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Adverse outcomes associated with Contact Precautions: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521583" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Contact precautions: more is not necessarily better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317398" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325727" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : "Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384220" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751155" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900759" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Impact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314063" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388005" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of daily chlorhexidine bathing on hospital-acquired infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20001537" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22482848" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954801" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476870" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171263" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Chlorhexidine: expanding the armamentarium for infection control and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23363666" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511128" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Effectiveness of stepwise interventions targeted to decrease central catheter-associated bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161233" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26631833" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26861417" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A Multicenter Pragmatic Interrupted Time Series Analysis of Chlorhexidine Gluconate Bathing in Community Hospital Intensive Care Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25739381" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Chlorhexidine skin or cord care for prevention of mortality and infections in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177667" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Hospital bath basins are frequently contaminated with multidrug-resistant human pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30803462" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effectiveness of daily chlorhexidine bathing for reducing gram-negative infections: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25602496" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Chlorhexidine bathing and health care-associated infections: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25603492" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Daily chlorhexidine bathing for critically ill patients: a note of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31476022" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628482" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16922622" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Triclosan and antimicrobial resistance in bacteria: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882683" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Triclosan and antibiotic resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882683" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Triclosan and antibiotic resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31442624" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571829" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37815567" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34609548" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35942379" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Meta-Analysis of the Efficacy and Safety of Chlorhexidine for Ventilator-Associated Pneumonia Prevention in Mechanically Ventilated Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36464582" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Does chlorhexidine reduce the incidence of ventilator-associated pneumonia in ICU patients? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33368159" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27778318" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30850551" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24663255" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798809" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35598950" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Should oral chlorhexidine remain in ventilator-associated pneumonia prevention bundles?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34092377" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Association between perioperative chlorhexidine oral care and postoperative pneumonia in non-cardiac surgical patients: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18179368" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589091" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687313" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25026607" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428482" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Associations Between Ventilator Bundle Components and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29744564" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Effects of chlorhexidine gluconate oral care on hospital mortality: a hospital-wide, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28890434" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118302" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Decontamination of the digestive tract and oropharynx in ICU patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420908" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36378275" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Selective Decontamination of the Digestive Tract: An Answer at Last?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33481250" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28497272" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Selective decontamination of the digestive tract halves the prevalence of ventilator-associated pneumonia compared to selective oral decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28870727" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148529" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Healthcare epidemiology: Ventilator-associated pneumonia: preventing the inevitable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25479466" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Use of selective digestive tract decontamination in European intensive cares: the ifs and whys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30347072" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185749" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965807" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271415" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375416" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Resistance to selective decontamination: the jury is still out.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271544" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36286097" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36286098" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Association Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285709" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334690" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347349" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21488763" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Intervention to reduce transmission of resistant bacteria in intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21488764" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491330" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Successful Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11852415" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27258068" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Isolation of C. difficile Carriers Alone and as Part of a Bundle Approach for the Prevention of Clostridium difficile Infection (CDI): A Mathematical Model Based on Clinical Study Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314222" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618523" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Detecting carbapenem-resistant Acinetobacter baumannii (CRAB) carriage: Which body site should be cultured?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980559" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Screening for Acinetobacter baumannii colonization by use of sponges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192537" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : An intervention to decrease catheter-related bloodstream infections in the ICU.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
